Doctronic

GLP-1 Shortage Update 2026: Which Medications Are Available

Key Takeaways

  • Semaglutide supplies have stabilized but intermittent shortages persist in certain dosage strengths

  • Tirzepatide availability has dramatically improved with expanded manufacturing capacity

  • Generic GLP-1 options and biosimilars are entering the market, providing more alternatives

  • Regional availability varies significantly based on pharmacy networks and distribution chains

The GLP-1 medication shortage that began in 2022 continues to evolve, with notable improvements in some areas while challenges persist for specific formulations and dosages. What started as a crisis affecting millions of diabetes and weight management patients has transformed into a more manageable supply situation, though not without ongoing complications.

Manufacturing capacity increases by major pharmaceutical companies have helped stabilize the market, but demand still frequently exceeds supply. Patients and healthcare providers must navigate this complex landscape with updated information and flexible treatment strategies. Doctronic's AI-powered platform can help patients understand their options and connect with healthcare providers who stay current on medication availability.

Current Supply Status Across Major GLP-1 Medications

The FDA shortage database shows partial resolution for brand-name semaglutide products, with significant improvements compared to the severe shortages of 2023-2024. Novo Nordisk and Eli Lilly have substantially increased their manufacturing capacity, leading to better overall supply stability across their GLP-1 product lines.

However, demand continues to exceed supply for weight loss indications despite these production improvements. The popularity of these medications for obesity treatment has created sustained pressure on manufacturing systems, even as companies ramp up production. Regional availability varies dramatically based on pharmacy networks and distribution chains, with some areas experiencing better access than others.

Specialty pharmacies often maintain better stock levels due to their direct relationships with manufacturers and their focus on complex medication management. This has created a two-tier system where patients with access to specialty pharmacy services may find medications more readily available.

When Shortages Impact Your Treatment Plan

New patients face 2-4 week delays for initial prescriptions in high-demand metropolitan areas, particularly for popular weight loss formulations. This delay can be frustrating for patients eager to start treatment, especially when dealing with conditions that benefit from prompt intervention.

Dose escalation schedules may be interrupted due to unavailable strength formulations, forcing healthcare providers to adjust treatment timelines. Insurance formulary changes create additional barriers when preferred medications are unavailable, sometimes requiring prior authorization processes that further delay treatment. Just as the ongoing doctor shortage affects access to care, medication shortages create similar accessibility challenges.

Rural and underserved areas experience more severe shortages due to limited pharmacy options and lower priority in distribution networks. These communities often rely on smaller independent pharmacies that may not have the purchasing power or relationships needed to secure consistent inventory.

How Modern Supply Chain Management Works

Pharmaceutical companies now allocate inventory based on updated historical prescribing patterns and demand forecasting models that account for the explosive growth in GLP-1 prescribing. These systems have become more refined since the initial shortage crisis, allowing for better distribution planning.

Specialty pharmacies receive priority allocation for complex cases and prior authorizations, creating a more reliable supply channel for patients with specific medical needs. Direct-to-patient shipping programs bypass traditional pharmacy constraints for eligible patients, though these services often come with additional costs and insurance complications.

Real-time inventory tracking systems help healthcare providers identify available alternatives when first-choice medications are unavailable. These systems represent a major improvement over the information gaps that characterized the early shortage period. The primary care physician shortage has made these technological solutions even more valuable for efficient medication management.

Available Medications and Supply Comparison

Understanding which specific formulations are available can help patients and providers make informed decisions about treatment options. Supply status varies significantly by dosage strength and brand.

Medication

Brand Names

Supply Status

Availability Rate

Semaglutide

Ozempic/Wegovy

Lower doses stable, higher doses intermittent

70-85%

Tirzepatide

Mounjaro/Zepbound

Significantly improved across all strengths

85-90%

Liraglutide

Victoza/Saxenda

Consistent supply maintained

90-95%

Dulaglutide

Trulicity

Good availability, lower demand

85-90%

Semaglutide injections in 0.25mg and 0.5mg strengths show much better availability than the 1mg and 2mg doses that remain subject to intermittent shortages. Tirzepatide supply has stabilized across all dosage strengths with approximately 85% pharmacy availability nationwide, representing one of the major success stories in shortage resolution.

Shortage Solutions vs Traditional Treatment Approaches

Modern medication switching protocols allow seamless transitions between available GLP-1 options when specific brands are unavailable. Healthcare providers have developed standardized approaches for converting between different GLP-1 medications while maintaining therapeutic effectiveness.

Combination therapy with metformin and SGLT2 inhibitors provides effective alternatives during shortages, often achieving similar glycemic control when GLP-1 medications are unavailable. Insulin therapy remains the most reliable backup option with consistent supply availability, though patient preference often favors newer medication classes.

Traditional diabetes management approaches may actually be preferred when GLP-1 access is consistently problematic in certain regions. Having backup plans and alternative treatment strategies has become an essential part of modern diabetes care, much like having a healthcare power of attorney provides security for medical decision-making.

Frequently Asked Questions

Compounded GLP-1 options remain heavily restricted due to FDA regulations on shortage exceptions. Most compounding pharmacies can only provide these medications when commercial versions are officially unavailable, and regulations change frequently based on supply status.

Online trackers provide general guidance but may not reflect real-time inventory at individual locations. Pharmacy apps are more reliable for specific store inventory, though they may not update immediately when stock levels change throughout the day.

Coverage varies by plan, but most insurers have policies allowing temporary switches to available alternatives. Prior authorization may be required, and patients should verify coverage before making changes to avoid unexpected costs.

Contact your healthcare provider immediately to discuss alternative dosing strategies or switching to a different GLP-1 medication. Don't attempt to adjust doses independently, as this can affect treatment effectiveness and safety.

Telehealth providers often have access to broader pharmacy networks and can quickly identify alternatives across different regions. They may also have relationships with specialty pharmacies that maintain better inventory levels than traditional retail pharmacies.

The Bottom Line

While GLP-1 shortages persist in 2026, supply stability has improved dramatically compared to the crisis conditions of 2023-2024. Multiple alternatives are now available, and better distribution systems help healthcare providers navigate availability challenges more effectively. Patients working with knowledgeable healthcare providers can successfully manage treatment continuity through medication switching and alternative strategies. The key to successful GLP-1 treatment during ongoing shortages lies in maintaining open communication with healthcare providers, staying flexible with treatment options, and utilizing specialty pharmacy services when available. Doctronic's AI-powered platform provides 24/7 access to healthcare guidance, helping patients understand their medication options and connect with licensed physicians who stay current on the latest availability information and treatment alternatives.

Ready to take control of your health? Get started with Doctronic today.

Related Articles